Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2023-07-13 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力2023年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2023 half-year performance forecast (业绩预告) for the period January 1 to June 30, 2023. It provides preliminary estimated net profit figures and explanations for changes compared to the prior year. It explicitly states that the data is preliminary, unaudited, and that the final accurate financial data will be disclosed in the formal 2023 half-year report. The document is short (1898 characters) and serves as an earnings preview rather than a full interim report containing actual financial statements or detailed analysis. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. H1 2023
2023-07-13 Chinese
天健会计师事务所关于公司2022年度营业收入扣除情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a specialized audit opinion on the deduction of operating revenue for the fiscal year 2022 of Tianjin Pharmaceutical Group Co., Ltd. It includes references to audited financial statements and a specific revenue deduction table prepared by management. The document is issued by a certified public accounting firm and provides a detailed audit opinion on a particular aspect of the financials, not the full annual report itself. The document length is short (1239 characters), but it contains substantive audit content rather than just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles excluding full annual reports. FY 2022
2023-06-09 Chinese
天士力关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving approval from the National Medical Products Administration for a clinical trial of a drug. It details the drug's basic information, research background, and risk warnings. The document is short (1324 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is an official regulatory announcement about a specific event related to the company. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-07 Chinese
天士力2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2022 annual dividend distribution by the company. It details the dividend per share, relevant dates for record and payment, the approval of the distribution plan at the 2023 shareholders meeting, tax treatment for different shareholders, and instructions for dividend payment. It does not contain full financial statements or comprehensive financial performance data, but rather focuses on dividend distribution details. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related shareholder information. The document length is under 5,000 characters and is clearly an announcement, not a full annual report or earnings release.
2023-05-15 Chinese
内蒙古建中律师事务所关于天士力医药集团股份有限公司差异化权益分派特殊除权除息事项之法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a specific corporate action: a differentiated rights distribution related to a special ex-dividend and ex-rights event for the company 天士力医药集团股份有限公司. It discusses legal compliance with company law, securities law, and stock repurchase guidelines, and provides detailed calculations and legal conclusions about the distribution. The document is not a financial report, earnings release, or management discussion, nor is it a regulatory announcement or certification. It is a standalone legal opinion related to a corporate action, which fits best under the category of Audit Report / Information (AR) as it involves legal and regulatory compliance opinions on a financial corporate action, but is not a full annual report or earnings release. The document length is under 5,000 characters, but it is a substantive legal opinion, not merely an announcement of a report publication or a certification letter. Therefore, the best classification is AR with high confidence. FY 2022
2023-05-15 Chinese
天士力关于参与设立生物医药股权投资合伙企业（有限合伙）暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company about its participation in establishing a biopharmaceutical equity investment partnership and related progress updates. It includes details about the investment amounts, partners, registration, and regulatory filings related to the fund. The document is relatively short (1331 characters) and serves as a progress announcement rather than a detailed financial report or regulatory filing. It does not contain financial statements, audit information, or management discussion. The content fits best with a Capital/Financing Update (CAP) as it relates to the company's investment and capital involvement in a new fund partnership.
2023-05-09 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.